menu
    • menu
    [{"orgOrder":0,"company":"AB2 Bio","sponsor":"WuXi Biologics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Tadekinig alfa","moa":"IL-18","graph1":"Immunology","graph2":"Phase III","graph3":"AB2 Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"AB2 Bio \/ AB2 Bio","highestDevelopmentStatusID":"10","companyTruncated":"AB2 Bio \/ AB2 Bio"},{"orgOrder":0,"company":"AB2 Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Tadekinig Alfa","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AB2 Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AB2 Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB2 Bio \/ Not Applicable"},{"orgOrder":0,"company":"AB2 Bio","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Protein","year":"2025","type":"Licensing Agreement","leadProduct":"Tadekinig Alfa","moa":"IL-18","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"AB2 Bio","amount2":0.68999999999999995,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0.68999999999999995,"dosageForm":"Subcutaneous Injection","sponsorNew":"AB2 Bio \/ Nippon Shinyaku","highestDevelopmentStatusID":"10","companyTruncated":"AB2 Bio \/ Nippon Shinyaku"}]

    Find Clinical Drug Pipeline Developments & Deals by AB2 Bio

    Menu

    AB2 Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AB2 Bio

                            Switzerland arrow
                            The Generic Rx Session
                            Not Confirmed

                            AB2 Bio

                            Switzerland arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tadekinig Alfa

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : Nippon Shinyaku

                            Deal Size : $686.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            AB2 Bio Signs U.S. Option and Licensing Agreement with Nippon Shinyaku for Tadekinig Alfa

                            Details : Under the licensing agreement, Nippon received an option to acquire exclusive U.S. rights to commercialize r-hIL-18BP (tadekinig alfa) to treat NLRC4-MAS.

                            Product Name : r-hIL-18BP

                            Product Type : Protein

                            Upfront Cash : $6.0 million

                            January 27, 2025

                            Lead Product(s) : Tadekinig Alfa

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : Nippon Shinyaku

                            Deal Size : $686.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AB2 Bio

                            Switzerland arrow
                            The Generic Rx Session
                            Not Confirmed

                            AB2 Bio

                            Switzerland arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tadekinig Alfa

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AB2 Bio Completes Enrolment in Pivotal Phase 3 Trial of Tadekinig alfa to Treat Primary Monogenic IL-18 Driven...

                            Details : r-hIL-18BP (tadekinig alfa) is a recombinant human interleukin-18 binding protein inhibiting IL18. It captures excess free IL-18 mimicking the normal physiological situation, and therefore represents a well differentiated approach for the treatment of IL...

                            Product Name : r-hIL-18BP

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 07, 2023

                            Lead Product(s) : Tadekinig Alfa

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AB2 Bio

                            Switzerland arrow
                            The Generic Rx Session
                            Not Confirmed

                            AB2 Bio

                            Switzerland arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tadekinig alfa

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Recipient : WuXi Biologics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            AB2 Bio and WuXi Biologics Announce Collaboration to Accelerate Commercial-Scale Manufacturing of Tadekinig al...

                            Details : Tadekinig alfa is a novel IL-18 binding protein in pivotal Phase 3 testing for orphan disease IL-18 driven monogenic Hemophagocytic Lymphohistiocytosis (HLH). WuXi Biologics to undertake commercial scale manufacturing to support U.S. market launch.

                            Product Name : r-hIL-18BP

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 29, 2020

                            Lead Product(s) : Tadekinig alfa

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Recipient : WuXi Biologics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth